Describes the factors faced by Roussel UCLAF, a French pharmaceutical company, in deciding whether and how to sell a controversial new drug, RU 486, which is often called the "French abortion pill." Decision Roussel part in its relations with the French government, its parent company, the German chemical giant Hoechst, supporters and opponents of abortion rights in France and the U.S., and the scientific community. The goal is to show students face a complex web of responsibilities of managers and the practical issues that arise conflicts between these obligations. "Hide
by Joseph L. Badaracco Jr., Christopher Sturr Source: Harvard Business School 12 pages. Publication Date: 02 Oct 1990. Prod. #: 391050-PDF-ENG
Related Case Solutions & Analyses:
Advance Technologies
The Bayan Tree
Kathy Giusti and the Multiple Myeloma Research Foundation
Are Voting Guidelines Ruling Your Business?
Hong Kong Business Intermediary: The Dynamic of Innovative Entrepreneurship
Marc Rich and Global Commodity Trading
Financing Higher Education in Australia
Logoplaste: Global Growing Challenges
Qualcomm Incorporated 2011 Update, Spanish Version
Royal Dutch/Shell in Nigeria (A), Chinese Version
